Expanding the Targets Available to Therapeutic Antibodies via Novel Disease-specific Markers

• Published in: International Reviews of Immunology Vol. 30; no. 5-6; pp. 312 - 327
• Main Authors: Weidanz, Jon A., Hildebrand, William H.
• Format: Journal Article
• Language: English
• Published: England Informa Healthcare 01.10.2011; Taylor & Francis
• Subjects: Antibodies, Monoclonal - immunology; Antibodies, Monoclonal - therapeutic use; Antibody Specificity; Cell Line, Tumor; Histocompatibility Antigens Class I - metabolism; Humans; Immunotherapy - methods; Molecular Mimicry; Neoplasms - immunology; Neoplasms - therapy; Peptides - metabolism; Receptors, Antigen, T-Cell - metabolism; T cell receptor mimics (TCRms), monoclonal antibodies (mAbs), Human Leukocyte Antigen (HLA), Major Histocompatibility Complex (MHC), epitope discovery, cancer therapy, immunotherapy, infectious disease therapy, mass spectrometry, CDC, ADCC
• ISSN: 0883-0185; 1937-4364; 1563-5244
• DOI: 10.3109/08830185.2011.608136

The development of immunotherapies offers significant promise for clinical applications in cancer and infectious diseases. Here the authors describe a novel, integrated approach to immunotherapy that combines novel technologies to discover and target disease-specific peptide/HLA class I complexes. This unique class of markers makes the entire proteome accessible to antibody reagents and offers unsurpassed specificity for targeting cancerous and infected cells. Arm one of the three-armed approach uses an innovative technology for the efficient, direct discovery of new peptide/HLA class I markers. Arm two applies a powerful and inventive strategy to generate T-cell receptor mimics (TCRms), which are antibodies with exquisite binding specificity for peptide/HLA class I markers, and uses TCRms to validate the specific expression of markers on cancerous and infected cells. The third arm uses TCRms to target and kill diseased cells with high sensitivity and specificity. In summary, the combination of two pioneering technologies expands the repertoire of disease-specific markers that can be targeted by therapeutic antibodies and enables a powerful, integrated approach to HLA-based immunotherapy.